SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:oru-99526"
 

Sökning: onr:"swepub:oai:DiVA.org:oru-99526" > Significant increas...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005904naa a2200565 4500
001oai:DiVA.org:oru-99526
003SwePub
008220615s2022 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-995262 URI
0247 a https://doi.org/10.1186/s12879-022-07509-w2 DOI
040 a (SwePub)oru
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Day, Michaela J.u UK Health Security Agency, London, UK4 aut
2451 0a Significant increase in azithromycin "resistance" and susceptibility to ceftriaxone and cefixime in Neisseria gonorrhoeae isolates in 26 European countries, 2019
264 c 2022-06-07
264 1b BioMed Central,c 2022
338 a print2 rdacarrier
500 a Funding agency:European Centre for Disease Prevention and Control ECDC/2017/004
520 a BACKGROUND: The European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP) performs annual sentinel surveillance of Neisseria gonorrhoeae susceptibility to therapeutically relevant antimicrobials across the European Union/European Economic Area (EU/EEA). We present the Euro-GASP results from 2019 (26 countries), linked to patient epidemiological data, and compared with data from previous years.METHODS: Agar dilution and minimum inhibitory concentration (MIC) gradient strip methodologies were used to determine the antimicrobial susceptibility (using EUCAST clinical breakpoints, where available) of 3239 N. gonorrhoeae isolates from 26 countries across the EU/EEA. Significance of differences compared with Euro-GASP results in previous years was analysed using Z-test and the Pearson's χ2 test was used to assess significance of odds ratios for associations between patient epidemiological data and antimicrobial resistance.RESULTS: European N. gonorrhoeae isolates collected between 2016 and 2019 displayed shifting MIC distributions for; ceftriaxone, with highly susceptible isolates increasing over time and occasional resistant isolates each year; cefixime, with highly-susceptible isolates becoming increasingly common; azithromycin, with a shift away from lower MICs towards higher MICs above the EUCAST epidemiological cut-off (ECOFF); and ciprofloxacin which is displaying a similar shift in MICs as observed for azithromycin. In 2019, two isolates displayed ceftriaxone resistance, but both isolates had MICs below the azithromycin ECOFF. Cefixime resistance (0.8%) was associated with patient sex, with resistance higher in females compared with male heterosexuals and men-who-have-sex-with-men (MSM). The number of countries reporting isolates with azithromycin MICs above the ECOFF increased from 76.9% (20/26) in 2016 to 92.3% (24/26) in 2019. Isolates with azithromycin MICs above the ECOFF (9.0%) were associated with pharyngeal infection sites. Following multivariable analysis, ciprofloxacin resistance remained associated with isolates from MSM and heterosexual males compared with females, the absence of a concurrent chlamydial infection, pharyngeal infection sites and patients ≥ 25 years of age.CONCLUSIONS: Resistance to ceftriaxone and cefixime remained uncommon in EU/EEA countries in 2019 with a significant decrease in cefixime resistance observed between 2016 and 2019. The significant increase in azithromycin "resistance" (azithromycin MICs above the ECOFF) threatens the effectiveness of the dual therapy (ceftriaxone + azithromycin), i.e., for ceftriaxone-resistant cases, currently recommended in many countries internationally and requires close monitoring.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Infektionsmedicin0 (SwePub)302092 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Infectious Medicine0 (SwePub)302092 hsv//eng
653 a Antimicrobial resistance
653 a Azithromycin
653 a Ceftriaxone
653 a Europe
653 a European Economic Area (EEA)
653 a European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP)
653 a European Union (EU)
653 a Gonorrhoea
653 a Surveillance
653 a Treatment
7001 a Jacobsson, Susanne,d 1974-u Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,WHO Collaborating Centre for Gonorrhoea and Other STIs4 aut0 (Swepub:oru)sajn
7001 a Spiteri, Gianfrancou European Centre for Disease Prevention and Control, Stockholm, Sweden4 aut
7001 a Kulishev, Carinau UK Health Security Agency, London, UK4 aut
7001 a Sajedi, Noshinu UK Health Security Agency, London, UK4 aut
7001 a Woodford, Neilu European Centre for Disease Prevention and Control, Stockholm, Sweden4 aut
7001 a Blumel, Benjaminu European Centre for Disease Prevention and Control, Stockholm, Sweden4 aut
7001 a van der Werf, Marieke J.u European Centre for Disease Prevention and Control, Stockholm, Sweden4 aut
7001 a Amato-Gauci, Andrew J.u European Centre for Disease Prevention and Control, Stockholm, Sweden4 aut
7001 a Unemo, Magnus,d 1970-u Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,WHO Collaborating Centre for Gonorrhoea and Other STIs, Örebro University, Örebro, Sweden; University College London (UCL), London, UK4 aut0 (Swepub:oru)muo
7001 a Cole, Michelle J.u UK Health Security Agency, London, UK4 aut
7001 a Euro-GASP network, -4 ctb
7102 a UK Health Security Agency, London, UKb Institutionen för medicinska vetenskaper4 org
7730 t BMC Infectious Diseasesd : BioMed Centralg 22:1q 22:1x 1471-2334
8564 u https://doi.org/10.1186/s12879-022-07509-wy Fulltext
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-99526
8564 8u https://doi.org/10.1186/s12879-022-07509-w

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy